Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT5TURO)

• DTT Name: A-Raf messenger RNA (ARAF mRNA)
• Synonyms: Serine/threonine-protein kinase A-Raf (mRNA); Proto-oncogene Pks (mRNA); Proto-oncogene A-Raf-1 (mRNA); Proto-oncogene A-Raf (mRNA); PKS2 (mRNA); PKS (mRNA); ARAF1 (mRNA)
• Gene Name: ARAF
• DTT Type: Clinical trial target; [1]
• Related Disease: Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• BioChemical Class: mRNA target
• UniProt ID: ARAF_HUMAN
• TTD ID: T88430
• EC Number: EC 2.7.11.1
• Sequence:
  MEPPRGPPANGAEPSRAVGTVKVYLPNKQRTVVTVRDGMSVYDSLDKALKVRGLNQDCCV
  VYRLIKGRKTVTAWDTAIAPLDGEELIVEVLEDVPLTMHNFVRKTFFSLAFCDFCLKFLF
  HGFRCQTCGYKFHQHCSSKVPTVCVDMSTNRQQFYHSVQDLSGGSRQHEAPSNRPLNELL
  TPQGPSPRTQHCDPEHFPFPAPANAPLQRIRSTSTPNVHMVSTTAPMDSNLIQLTGQSFS
  TDAAGSRGGSDGTPRGSPSPASVSSGRKSPHSKSPAEQRERKSLADDKKKVKNLGYRDSG
  YYWEVPPSEVQLLKRIGTGSFGTVFRGRWHGDVAVKVLKVSQPTAEQAQAFKNEMQVLRK
  TRHVNILLFMGFMTRPGFAIITQWCEGSSLYHHLHVADTRFDMVQLIDVARQTAQGMDYL
  HAKNIIHRDLKSNNIFLHEGLTVKIGDFGLATVKTRWSGAQPLEQPSGSVLWMAAEVIRM
  QDPNPYSFQSDVYAYGVVLYELMTGSLPYSHIGCRDQIIFMVGRGYLSPDLSKISSNCPK
  AMRRLLSDCLKFQREERPLFPQILATIELLQRSLPKIERSASEPSLHRTQADELPACLLS
  AARLVP
• Function: May also regulate the TOR signaling cascade. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus.
• KEGG Pathway:
  ErbB signaling pathway (hsa04012)
  FoxO signaling pathway (hsa04068)
  Vascular smooth muscle contraction (hsa04270)
  Natural killer cell mediated cytotoxicity (hsa04650)
  Long-term potentiation (hsa04720)
  Serotonergic synapse (hsa04726)
  Long-term depression (hsa04730)
  Regulation of actin cytoskeleton (hsa04810)
  Insulin signaling pathway (hsa04910)
  Progesterone-mediated oocyte maturation (hsa04914)
  Alcoholism (hsa05034)
  Hepatitis C (hsa05160)
  Pathways in cancer (hsa05200)
  Proteoglycans in cancer (hsa05205)
  Colorectal cancer (hsa05210)
  Renal cell carcinoma (hsa05211)
  Pancreatic cancer (hsa05212)
  Endometrial cancer (hsa05213)
  Glioma (hsa05214)
  Prostate cancer (hsa05215)
  Melanoma (hsa05218)
  Bladder cancer (hsa05219)
  Chronic myeloid leukemia (hsa05220)
  Acute myeloid leukemia (hsa05221)
  Non-small cell lung cancer (hsa05223)
• Reactome Pathway:
  MAP2K and MAPK activation (R-HSA-5674135)
  Negative regulation of MAPK pathway (R-HSA-5675221)
  RAF activation (R-HSA-5673000)

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7304	DMGFAVQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

13 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 10228	DMESKQX	Discovery agent	N.A.	Investigative	[2]
ISIS 9060	DMZL7SW	Discovery agent	N.A.	Investigative	[3]
ISIS 9061	DMFAL2E	Discovery agent	N.A.	Investigative	[3]
ISIS 9062	DM5ZGSO	Discovery agent	N.A.	Investigative	[3]
ISIS 9063	DM8E5RO	Discovery agent	N.A.	Investigative	[3]
ISIS 9064	DMBMTGP	Discovery agent	N.A.	Investigative	[3]
ISIS 9065	DMH50RX	Discovery agent	N.A.	Investigative	[3]
ISIS 9066	DMB8MH0	Discovery agent	N.A.	Investigative	[3]
ISIS 9067	DML8HCZ	Discovery agent	N.A.	Investigative	[3]
ISIS 9068	DM953VY	Discovery agent	N.A.	Investigative	[3]
ISIS 9069	DM5C86M	Discovery agent	N.A.	Investigative	[3]
ISIS 9070	DMU0HQF	Discovery agent	N.A.	Investigative	[3]
ISIS 9071	DMWY2XB	Discovery agent	N.A.	Investigative	[3]

References

• [1] Clinical pipeline report, company report or official report of Roche.
• [2] US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression.
• [3] US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression.